Back to Search Start Over

Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study

Authors :
Raquel López-Vilella
Víctor Donoso Trenado
Pablo Jover Pastor
Ignacio Sánchez-Lázaro
Luis Martínez Dolz
Luis Almenar Bonet
Source :
Life, Vol 12, Iss 11, p 1828 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Background. This study aims to determine whether the administration of ferric carboxymaltose (FCM) in patients with acute heart failure (AHF) and iron deficiency (ID) improves morbidity and mortality. Methods. We studied 890 consecutive patients admitted for AHF. Patients were divided into six groups according to reduced left ventricular ejection fraction (HFrEF) or preserved (HFpEF), presence of ID, and administration of FCM. Emergency visits, re-admissions, and all-cause mortality were assessed at 6 months. Results. The overall prevalence of ID was 91.2%. In the HFrEF group, no differences were found in isolated events when patients with untreated vs. treated ID were compared, while differences were found in the combined event rate (p = 0.049). The risk calculation showed an absolute risk reduction (ARR) of 10% and relative risk reduction (RRR) of 18%. In HFpEF there was a positive trend with regard to the combined event (p = 0.107), with an ARR of 9% and an RRR of 15%. The number of patients we needed to treat to prevent a combined event was 10.5 in HFrEF and 10.8 in HFpEF. Conclusions. FCM in AHF reduced the combined event rate of emergency visits, re-admission, and all-cause death at 6 months in HF with left ventricular ejection fraction

Details

Language :
English
ISSN :
20751729
Volume :
12
Issue :
11
Database :
Directory of Open Access Journals
Journal :
Life
Publication Type :
Academic Journal
Accession number :
edsdoj.96bba00a87684ead93aaab63a3eb1b0d
Document Type :
article
Full Text :
https://doi.org/10.3390/life12111828